Max has written a variety of stories spanning enterprise, news analysis, scientific advancements and more. You can find links to his best work, as well as PDFs, below.
Features/enterprise stories:
- How pharma is capitalizing on the sudden revival and success of an old asthma drug | PDF
- More data, costly standards and no end in sight: Pharma grapples with its clinical trials cost problem | PDF
- Drugmakers seize on biomarkers to test the FDA’s rare disease shift | PDF
- Biotech industry worries over potential for RFK Jr. ally as FDA pick | PDF
- Vivek Ramaswamy is running an anti-“woke,” anti-China presidential campaign. It’s a contrast to his time as CEO | PDF
- A simple patient survey revolutionized ALS drug development in the 1990s. Its creator says it may be time for an upgrade | PDF
Emerging cancer beat (PD-1xVEGF bispecifics):
- Are PD-1xVEGF bispecifics being tested in the wrong kinds of cancer? | PDF
- Summit plays defense for the first time as questions loom over Phase 3 lung cancer readouts | PDF
- Pfizer has a VEGF bispecific strategy. And it’s very different than Summit’s | PDF
- After a frenzied year of dealmaking, here’s how the PD-(L)1xVEGF bispecific race is looking so far | PDF
- Q&A: BioNTech co-founders discuss bispecific efforts, Bristol Myers deal, and the irony of competing with Pfizer | PDF
Corporate analysis stories:
- How Merck is mounting a patent defense for Keytruda, its $150B cash cow | PDF
- How expensive would a Revolution Medicines buyout be after its Phase 3 win? | PDF
- Is this pancreatic cancer’s ‘Herceptin moment’? Revolution Medicines’ breakthrough offers hope | PDF
- Caught in FDA’s rare disease crackdown, uniQure seeks ethical path forward for Huntington’s treatment | PDF
- Ahead of FDA decision, Alnylam faces the big question: Can it make money? | PDF
Clinical trial stories:
- Biogen won’t be ‘impulsive’ with anti-tau Alzheimer’s drug | PDF
- AstraZeneca details its oral SERD ‘switching’ regimen as feasibility questions remain | PDF
- Sanofi’s Phase 3 eczema data cloud hopes for potential immunology blockbuster | PDF
- Exclusive: How Seaport is hedging against failure in Phase 2b depression study | PDF
- Bristol Myers’ Krazati fails confirmatory trial in colorectal cancer, putting approval at risk | PDF
Earnings stories:
- As AbbVie posts more strong Skyrizi sales, Wall Street frets over J&J pill | PDF
- Shedding caution, J&J makes bold claims for sales growth. Will it happen? | PDF
- Sanofi’s new CEO faces a reckoning on immunology-focused R&D strategy | PDF
- Bristol Myers reaches a crossroads as a make-or-break year takes shape | PDF
- The BridgeBio and Alnylam rivalry in ATTR-CM may not be a race at all. What gives? | PDF
Science stories:
- Broad Institute paper offers potential new framework for treating Huntington’s disease | PDF
- Roche doubles down on its Alzheimer’s ambitions as next-gen amyloid-lowering drug excites scientists | PDF
- Academic trial suggests modest GLP-1 effect in Parkinson’s disease, but questions remain | PDF
- Advocates, experts cry foul over Amylyx’s new ALS drug, citing issues with price, PhIII commitment | PDF
Max Gelman 